To the content

Key Publications.

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Author
Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A
Publication Year
2023
Source
NEJM Evidence. 2023 May 23;2(6):EVIDoa2200335

PROUD-PV Study Group. Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b.

Author
Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Empson V, Hasselbalch HC, Kralovics R, Gisslinger H
Publication Year
2022
Source
Leukemia. 2022 May;36(5):1408-1411. DOI: 10.1038/s41375-022-01528-x

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.

Author
Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A
Publication Year
2021
Source
Lancet Haematol. 2021 Mar;8(3):e175-e184. DOI: 10.1016/S2352-3026(20)30373-2

Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.

Author
Jäger R, Gisslinger H, Fuchs E, Bogner E, Milosevic Feenstra JD, Weinzierl J, Schischlik F, Gisslinger B, Schalling M, Zörer M, Krejcy K, Klade C, Kralovics R
Publication Year
2021
Source
Blood. 2021 Jan 21;137(3):387-391. DOI: 10.1182/blood.2020005792

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Author
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Hasselbalch HC, Kralovics R, Kiladjian JJ
Publication Year
2020
Source
Hemasphere. 2020 Oct 20;4(6):e485. DOI: 10.1097/HS9.0000000000000485

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Author
Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ
Publication Year
2020
Source
PROUD-PV Study Group. Lancet Haematol. 2020 Mar;7(3):e196-e208. DOI: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31. Erratum in: Lancet Haematol. 2020 Feb 25

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Author
Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z, Kralovics R, Gisslinger H, Grohmann-Izay B, Klade C, Chomienne C, Giraudier S, Cassinat B, Kiladjian JJ
Publication Year
2018
Source
Blood Cancer J. 2018 Oct 4;8(10):94. DOI: 10.1038/s41408-018-0133-0

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Author
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R
Publication Year
2015
Source
Blood. 2015 Oct 8;126(15):1762-9. DOI: 10.1182/blood-2015-04-637280

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

Author
Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R
Publication Year
2015
Source
Am J Hematol. 2015 Apr;90(4):288-94. DOI: 10.1002/ajh.23928

Hemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target.

Author
Gerges C, Montani D, Humbert M, Lang IM
Publication Year
2024
Source
European Respiratory Journal. 2024 Jan 1. DOI: 10.1183/13993003.02280-2023

The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil - PubMed (nih.gov).

Author
Jansa P, Kopeć G, Torbicki A, Sadushi-Kolici R, Campean IA, Halank M, Simkova I, Steringer-Mascherbauer R, Salobir B, Klepetko W, Lindner J, Lang IM
Publication Year
2023
Source
Pulm Circ. 2023 Aug 21;13(3):e12274. doi: 10.1002/pul2.12274

Rapid Switch From Subcutaneous to Intravenous Treprostinil in Precapillary Pulmonary Hypertension by Pump Implantation.

Author
Steringer-Mascherbauer R, Maria L, Reinhold F, Elisabeth S, Charlotte H, Dagmar E, Uwe F, Josef A
Publication Year
2021
Source
J Cardiovasc Pharmacol. 2021 Jan 1;77(1):38-42. DOI: 10.1097/FJC.0000000000000933

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension-procedural safety and system-related complications.

Author
Steringer-Mascherbauer R, Lummersdorfer M, Függer R, Sigmund E, Huber C, Engleder D, Fröschl U, Aichinger J
Publication Year
2020
Source
Pulm Circ. 2020 Nov 30;10(4). DOI: 10.1177/2045894020970830

Regimen-dependent synergism and antagonism of treprostinil and vildagliptin in hematopoietic cell transplantation.

Author
Zebedin-Brandl E, Themanns M, Kazemi Z, Nasrollahi-Shirazi S, Mussbacher M, Heyes E, Meissl K, Prchal-Murphy M, Strohmaier W, Krumpl G, Freissmuth M
Publication Year
2020
Source
J Mol Med (Berl). 2020 Feb;98(2):233-243. doi: 10.1007/s00109-019-01869-8. Epub 2019 Dec 24

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.

Author
Sadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA, Halank M, Simkova I, Karlocai K, Steringer-Mascherbauer R, Samarzija M, Salobir B, Klepetko W, Lindner J, Lang IM
Publication Year
2019
Source
Lancet Respir Med. 2019 Mar;7(3):239-248

Heart rate control with landiolol hydrochloride in infants with ventricular dysfunction and pulmonary hypertension.

Author
Schroeder L, Monno P, Unger M, Ackerl J, Shatilova O, Schmitt J, Dresbach T, Mueller A, Kipfmueller F
Publication Year
2023
Source
ESC Heart Fail. 2023 Feb;10(1):385-396. DOI: 10.1002/ehf2.14202

Blood Pressure Recovery After Dobutamine Antagonism: Partial With Landiolol, None With Esmolol.

Author
Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J, Husch B
Publication Year
2022
Source
Clin Pharmacol Drug Dev. 2022 Mar;11(3):309-317. doi: 10.1002/cpdd.1025. Epub 2021 Oct 16. PMID: 34655181. DOI: 10.1002/cpdd.1025

Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults.

Author
Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J
Publication Year
2020
Source
BMC Pharmacol Toxicol. 2020 Nov 25;21(1):82. DOI: 10.1186/s40360-020-00462-x

Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.

Author
Stix G, Wolzt M, Domanovits H, Kadlecová P, Husch B, Trebs M, Hodisch J, Unger M, Krumpl G
Publication Year
2019
Source
Circ J. 2019 Dec 25;84(1):33-42. DOI: 10.1253/circj.CJ-19-0661

Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.

Author
Unger M, Morelli A, Singer M, Radermacher P, Rehberg S, Trimmel H, Joannidis M, Heinz G, Cerny V, Dostál P, Siebers C, Guarracino F, Pratesi F, Biancofiore G, Girardis M, Kadlecova P, Bouvet O, Zörer M, Grohmann-Izay B, Krejcy K, Klade C, Krumpl G
Publication Year
2018
Source
Trials. 2018 Nov 19;19(1):637. doi: 10.1186/s13063-018-3024-6. PMID: 30454042; PMCID: PMC6245811. DOI: 10.1186/s13063-018-3024-6

Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites.

Author
Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J, Maurer G, Husch B
Publication Year
2018
Source
J Cardiovasc Pharmacol. 2018 Mar;71(3):137-146. DOI: 10.1097/FJC.0000000000000554

Pharmacodynamic and -kinetic Behavior of Low-, Intermediate-, and High-Dose Landiolol During Long-Term Infusion in Whites.

Author
Krumpl G, Ulč I, Trebs M, Kadlecová P, Hodisch J, Maurer G, Husch B
Publication Year
2017
Source
J Cardiovasc Pharmacol. 2017 Jul;70(1):42-51. DOI: 10.1097/FJC.0000000000000495

Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Author
Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J
Publication Year
2017
Source
Eur J Clin Pharmacol. 2017 Apr;73(4):417-428. DOI: 10.1007/s00228-016-2176-0

Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group.

Author
Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J
Publication Year
2016
Source
Eur J Pharm Sci. 2016 Sep 20;92:64-73. DOI: 10.1016/j.ejps.2016.06.022

Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol.

Author
Krumpl G, Ulč I, Trebs M, Hodisch J, Kadlecová P, Husch B
Publication Year
2020
Source
Cureus. 2020 Dec 22;12(12):e12217. DOI: 10.7759/cureus.12217

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.

Author
Gisslinger H, Buxhofer-Ausch V, Hodisch J, Radinoff A, Karyagina E, Kyrcz-Krzemień S, Abdulkadyrov K, Gerbutavicius R, Melikyan A, Burgstaller S, Hus M, Kłoczko J, Yablokova V, Tzvetkov N, Całbecka M, Shneyder T, Warzocha K, Jurgutis M, Kaplanov K, Jilma B, Schoergenhofer C, Klade C
Publication Year
2019
Source
Br J Haematol. 2019 May;185(4):691-700. DOI: 10.1111/bjh.15824

Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product.

Author
Petrides PE, Schoergenhofer C, Widmann R, Jilma B, Klade CS
Publication Year
2018
Source
Clin Pharmacol Drug Dev. 2018 Feb;7(2):123-131. DOI: 10.1002/cpdd.34002.008

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Author
Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE
Publication Year
2013
Source
Blood. 2013 Mar 7;121(10):1720-8. DOI: 10.1182/blood-2012-07-443770

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.

Author
Petrides PE, Gisslinger H, Steurer M, Linkesch W, Krumpl G, Schüller A, Widmann R
Publication Year
2009
Source
R. Clin Ther. 2009 Feb;31 (2):386-98. DOI: 10.1016/j.clinthera.2009

Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.

Author
Steurer M, Gasti G, Jedrzejczak WW, Pytlik R, Lin W, SchlogI E, Gisslinger H. Cancer
Publication Year
2004
Source
Cancer. 2004 Nov 15;101 (10):2239-46. DOI: 10.1002/cncr.20646

Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone.

Author
Peball M, Krismer F, Knaus HG, Djamshidian A, Werkmann M, Carbone F, Ellmerer P, Heim B, Marini K, Valent D, Goebel G, Ulmer H, Stockner H, Wenning GK, Stolz R, Krejcy K, Poewe W, Seppi K
Publication Year
2020
Source
Collaborators of the Parkinson's Disease Working Group Innsbruck. Ann Neurol. 2020 Oct;88(4):712-722

Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study).

Author
Peball M, Werkmann M, Ellmerer P, Stolz R, Valent D, Knaus HG, Ulmer H, Djamshidian A, Poewe W, Seppi K
Publication Year
2019
Source
J Neural Transm (Vienna). 2019 Aug;126(8):1061-1072
To the main navigation